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Mini-Abstract 
Sinusoidal obstruction syndrome (SOS) induced by chemotherapy is of concern in 
hepatectomy for patients with hepatic colorectal metastases. We succeeded in inhibiting the 
occurrence of SOS in a rat model through induction of heme oxygenase-1 by pretreatment 




Objective: The aim of study was to investigate pharmacological treatment for sinusoidal 
obstruction syndrome (SOS). 
Background: SOS is associated with oxaliplatin-based chemotherapy in patients with hepatic 
colorectal metastases. Patients with SOS have increased postoperative morbidity after major 
hepatectomy, but a method for effective prevention of SOS has not been established. 
Methods: Male Sprague-Dawley rats were treated with cobalt protoporphyrin IX (CoPP) or 
olprinone (OLP), a phosphodiesterase III inhibitor, and hepatic HO-1 expression and HO 
enzymatic activity were determined. Monocrotaline (MCT) was given to rats to induce SOS, 
and blockage of SOS by CoPP or OLP-induced hepatic HO-1 was examined in these rats. 
Zinc protoporphyrin IX (ZnPP), a competitive HO inhibitor, was given to MCT-treated rats 
together with OLP to clarify the mechanism of protection against SOS. We also examined if 
OLP preserved remnant liver function after 70% hepatectomy in MCT-treated rats. 
Results: OLP upregulated hepatic HO-1 protein expression and HO enzymatic activity, and 
activated Akt protein. Administration of ZnPP to OLP-treated rats resulted in inhibition of HO 
activity and inactivation of Akt. Induction of HO-1 by pretreatment with CoPP led to 
amelioration of SOS in histological findings and blockage of elevation of serum liver 
enzymes. Pretreatment with OLP gave a similar result and preserved remnant liver function, 
as indicated by improved survival after hepatectomy. ZnPP completely abolished the 
protective effects of OLP. 
Conclusions: Protection of the liver from drug-induced injury by prior upregulation of HO-1 




Surgical resection is the standard treatment for patients with hepatic colorectal metastases 
(HCRM) and is only the therapy leading to cure.
1
 Recent regimens of neoadjuvant 
chemotherapy using 5-fluorouracil (5FU) and leucovorin combined with new anti-cancer 





 Therefore, chemotherapy regimens containing these new agents have become the 
standard of care in this setting.
4
 However, use of these new agents requires caution, since 
hepatic vascular alterations, such as sinusoidal dilatation and hemorrhage, identical with those 
of sinusoidal obstruction syndrome (SOS) are observed in 79% of hepatectomy specimens 
from patients treated with oxaliplatin-based neoadjuvant chemotherapy.
5
  
Dietary ingestion of pyrrolizidine alkaloids and cytotoxic drugs such as azathioprine, 
cyclophosphamide, busulfan and dacarbazine are well known as major causes of SOS,
6
 and 




 The sinusoidal alterations in 
the liver result in bluish discoloration, edema, and a spongiform consistency similar to that of 
early cirrhosis. These phenomena, which are referred to as blue liver syndrome, increase 




 but a method for 
effective prevention of SOS has not been established. Furthermore, the preoperative diagnosis 
of SOS after oxaliplatin-based chemotherapy is often overlooked because SOS may be present 
despite a normal liver function test.
9
 However, if hepatic resection is performed without 





Additionally, once SOS occurs the sinusoidal lesions persist for several months after 
completion of chemotherapy regimens,
5
 and this may affect the timing of curative resection 
for HCRM. Therefore, chemotherapy-induced SOS may have a negative impact on curative 
resection of HCRM, despite successful tumor regression by neoadjuvant chemotherapy. This 
background suggests that a strategy for prevention of SOS is required to optimize the potential 
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for liver resection. 
The heme oxygenase (HO) enzyme system is a current area of study because of its 
cytoprotective properties. HO-1, the inducible isoform of the HO family, is of particular 
interest because it is upregulated in response to pathologic stimuli such as hypoxia, 
endotoxicemia, hemorrhagic shock, and drug-induced liver injury to maintain cellular 
function against sublethal stress in almost all organs, including the liver.
13
 However, no 
clinical trial associated with HO-1 has been reported to date. The cause of SOS is considered 
to be insult of sinusoidal endothelial cells (SECs) induced by chemical agents,
8
 and therefore 
protection of SECs may be the key to a preventive strategy for SOS. In the current study, we 
focused on olprinone (OLP), a phosphodiesterase (PDE) III inhibitor that has a protective 
effect on SECs in vivo.
14
 The purpose of the study was to investigate the pathogenesis of SOS 
and examine pharmacological prevention of SOS by induction of HO-1 by OLP. 
 
Materials and Methods 
Reagents 
Monocrotaline (MCT) was purchased from Sigma Aldrich (St. Louis, MO). To prepare a 
solution of MCT at 10mg/ml, 500 mg of MCT was dissolved in 1.0 N HCl and the pH was 
adjusted to 7.4 with 0.5 N NaOH.
15
 PBS (pH 7.4) was added to increase the total volume to 50 
ml. Olprinone (OLP), a phosphodiesterase (PDE) III inhibitor (Eisai Pharmaceutical Co. 
Tokyo, Japan), was dissolved in distilled water. Zinc protoporphyrin IX (ZnPP), competitive 
HO enzymatic activity inhibitor,
16
 and cobalt protoporphyrin IX (CoPP), HO-1 inducer, were 
purchased from Frontier Scientific Europe (Carnforth, UK). To prepare solutions of ZnPP at 2 
mg/ml and CoPP at 1 mg/ml, each was dissolved in 0.2 N NaOH and the pH was adjusted to 
7.4 with 1 N HCl.
17
 PBS (pH 7.4) was added to increase the total volume as appropriate. All 




Male Sprague-Dawley rats of 7-8 weeks of age and weighing 250 ± 50 g were obtained 
from SLC (Shizuoka, Japan). The animals had free access to food and water. The 
experimental protocol was approved by the Animal Research Committee of Kyoto University, 
and all animals received humane care according to NIH Guidelines for the Care and Use of 
Laboratory Animals. 
Monocrotaline (MCT)-treated rats were used as an experimental model of sinusoidal 
obstruction syndrome (SOS); this approach has previously been reported as a reproducible 
model of SOS.
18
 Rats were fasted 12 h before MCT treatment, but were allowed water ad 
libitum. MCT (90 mg/kg) was administered by gavage and the rats were then allowed food 
and water ad libitum. A comparison between oxaliplatin-induced human SOS and 
MCT-induced rat SOS is shown in Figure 1. Photomicrographs of liver sections (Figs. 1A and 
1C) from a 58-year-old patient with SOS were obtained by liver biopsy two weeks after 
completion of 6 cycles of oxaliplatin-based chemotherapy (FOLFOX6), which were 
performed after 3 cycles of irinotecan-based chemotherapy (FOLFIRI) for unresectable liver 
metastases from rectal cancer. HE staining revealed sinusoidal congestion and dilatation, 
coagulative necrosis of hepatocytes, and recruitment of neutrophils (Fig. 1A), and 
Masson-Trichrome staining showed peri-central fibrosis (Fig. 1C). Histopathological changes 
in rats after treatment with 90 mg/kg MCT occurred in four phases. Early manifestation of 
toxicity, as indicated by mild sinusoidal hemorrhage and dilation, and mild damage to the 
endothelium of the central vein started on day 1. On days 2 and 3, severe sinusoidal changes 
and damage to the endothelium of the central vein, coagulative necrosis of hepatocytes, and 
recruitment of neutrophils were observed (Fig. 1B). The histopathological changes in this 
phase are similar to those in human SOS. On days 4 to 6, the histological liver insults 
gradually attenuated, while perivenular fibrosis was observed in areas surrounding central 
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veins (Fig. 1D). After day 7, almost all animals had fully recovered. Based on these results, 
histopathological and biochemical analyses were performed at 48 h after MCT treatment, 
since histopathological changes in this period are most similar to those in human SOS. 
 
Assessment of hepatic HO-1 expression following pharmacological treatment 
To investigate hepatic HO-1 expression, CoPP or OLP was administered to rats. CoPP 
was given via a single intraperitoneal (ip) injection (5.0 mg/kg) and liver tissues were 
collected at 6, 12, 24 and 48 h after CoPP treatment (n = 2 for each time point). Rats receiving 
OLP were divided into two groups. In the first group, an Alzet
®
 osmotic pump (Model 2001; 
Durect Corp., Cupertino, CA, USA) was inserted into the peritoneal cavity under anesthesia 
with sevoflurane (Abbott Japan, Osaka, Japan) to facilitate OLP administration via continuous 
ip injection (0.6μg/kg/min). At 12 h after insertion of the osmotic pump, the rats also received 
a single ip injection of OLP (2.0 mg/kg). Rats of the second group were treated with only a 
single ip injection of OLP (2.0 mg/kg) without insertion of an osmotic pump. Liver tissues 
were obtained at 6, 12, 24, and 48 h after the single ip injection of OLP (n = 4 for each time 
point) and hepatic HO-1 expression, phosphorylation of Akt, Akt, and HO enzymatic activity 
were assessed at each time point. Liver tissues were also obtained from untreated normal rats 
(n = 4) as a control. 
Additionally, ZnPP was administered intraperitoneally to OLP-treated rats of the first 
group simultaneously with a single ip injection of OLP. Liver tissues were obtained similarly 
as described above. 
 
Assessment of the effect of CoPP on HO-1 in MCT-treated rats 
The animals were divided into 4 groups: control, MCT alone, MCT+CoPP, and 
MCT+CoPP+ZnPP (n = 6 in each group). In the MCT+CoPP group, CoPP was administered 
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12 h before MCT treatment via a single ip injection (5.0 mg/kg). In the MCT+CoPP+ZnPP 
group, ZnPP (50 μmol/l) was given intraperitoneally at the same time of MCT treatment. Rats 
of the control group received PBS by gavage instead of MCT. At 48 h after MCT or PBS 
treatment, blood and liver samples were collected following ip injection of 40 mg/kg of 
pentobarbital. Serum was separated for measurement of aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT). 
 
Assessment of the effect of OLP pretreatment on MCT-treated rats 
Rats were divided into 3 groups: MCT, MCT+OLP, and MCT+OLP+ZnPP (Fig. 2). All 
animals were treated with MCT as described above. In the MCT+OLP and MCT+OLP+ZnPP 
groups, an Alzet
®
 osmotic pump was inserted into the peritoneal cavity 12 h before MCT 
treatment to facilitate continuous ip injection of OLP (0.6 μg/kg/min) until the end of the 
protocol. A single ip injection of OLP (2.0 mg/kg) was given simultaneously with the MCT 
treatment. In the MCT group, distilled water was administered instead of OLP. In the 
MCT+OLP+ZnPP group, ZnPP (50 μmol/l) was given via a single ip injection simultaneously 
with MCT treatment. Liver tissues and blood samples were collected 12 h after MCT 
treatment to investigate the expression of HO-1 protein and HO enzymatic activity in each 
group (n = 3), and 48 h after MCT treatment to assess the degree of liver injury in each group 
(n = 6). 
 
Assessment of OLP pretreatment on survival of MCT-treated rats after partial 
hepatectomy 
Survival in the MCT, MCT+OLP, and MCT+OLP+ZnPP groups (see previous section) 
was evaluated after partial hepatectomy (n = 15 in each group). The rats underwent 





pump was removed during hepatectomy to avoid inotropic effects of OLP in the postoperative 
period. Surgical procedures were performed under anesthesia with sevoflurane (Abbott Japan). 
After laparotomy through median incision, the left lateral and middle hepatic lobes were 
ligated and removed. During the procedure, oxygen inhalation was given via a mask and body 
temperature was maintained at 36.5 to 37.5ºC using a heated table. After surgery, the rats were 
allowed food and water ad libitum and monitored for 10 days. 
 
Liver histology 
Liver tissues were fixed with 4% paraformaldehyde, embedded in paraffin wax and 
sectioned at 4 μm. The slides were stained with hematoxylin and eosin (HE) and histological 
assessment of SOS was performed blindly by a pathologist (A. M-H.). To quantify the degree 
of SOS, histological changes of the following three parameters were reviewed according to 
the scoring system described by Deleve et al.
18
: endothelial damage of the central vein; 
coagulative necrosis of hepatocytes; and sinusoidal hemorrhage. Each parameter was graded 
on a 4-point scale: 0 = absent; 1 = mild; 2 = moderate; 3 = severe. To classify SOS, an overall 
score was determined by adding up individual scores, with a total HE score of < 2 , 2 to 3, 4 to 
6, and 7 to 9 points classified as absent, mild, moderate and severe SOS, respectively. 
 
Immunohistochemistry 
For immunohistochemistry of HO-1, paraffin sections were pretreated with 0.3% H2O2 in 
methanol and then subjected to antigen retrieval in citrate buffer (10 mM, pH 6.0) in a 
pressure cooker. After blocking with 3% BSA-10% normal serum for 1 h, the sections were 
incubated with a primary antibody recognizing HO-1 (# SPA-896; Stressgene, Victoria, 
Canada) at 1:200 dilution overnight at 4°C. Subsequently, the sections were incubated with 
Labeled Polymer in an Envision + System HRP Kit (Dako, Tokyo, Japan) at room temperature 
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for 1 h. The sections were examined after incubation with a Liquid DAB Substrate 
Chromogen System (Dako) and counterstained with hematoxylin.  
In immunostaining for rat endothelial cell antigen (RECA)-1 (#MCA-970R; Serotec, 
Oxford, UK), tissue samples were directly embedded in O.C.T. compound (Sakura Finetek, 
Tokyo, Japan) and sectioned at 6 μm. The sections were fixed with 4% paraformaldehyde for 
10 min at 4°C. After blocking, the sections were incubated with a primary antibody 
recognizing RECA-1 at 1:50 dilution for 1 h at 4°C 
19
. Immunostaining signals were 
visualized using Labeled Polymer in an Envision + System HRP Kit (Dako). 
 
Western blot analysis 
Tissue samples were homogenized in lysis buffer containing 50mM Tris-HCl (pH 6.8), 
10% glycerol and 2% sodium dodecylsulfate. After the concentration of the sample was 
determined, 0.1% bromophenol blue and 5% 2-mercaptoethanol was added. For 
immunoblotting, protein (24 μg) was subjected to 15% SDS-PAGE. After electrophoresis, the 
protein was transferred to a polyvinylidene difluoride membrane. The membranes were 
blocked with Blocking-One (Nacalai Tesque, Kyoto, Japan) and incubated with a primary 
antibody recognizing HO-1, Akt phosphorylated at Ser
473 
(#9271S; Cell Signaling, Beverly, 
Mass), or α-tubulin (#CP06; Calbiochem, San Diego, CA, USA) at 1:1000 dilution overnight 
at 4°C. After washing, membranes were reacted with horseradish peroxidase-conjugated 
antibodies (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). Chemiluminescence was 
detected with Immobilon Western HRP Substrate (Millipore, Billerica, MA, USA) and the 
intensity of the bands was quantified with Quantity One imaging analysis software (Bio-Rad 
Laboratories, CA, USA). Phosphorylated Akt blot was subsequently stripped using WB 
stripping solution (Nakarai Tesque) at 37 °C, and was re-probed with primary antibody 





Determination of HO enzymatic activity 
The HO enzymatic activity was measured following the method of Taylor et al.
20
 In brief, 
frozen liver tissues were homogenized on ice in 100mM phosphate buffer with 2mM MgCl2 
(HO activity buffer). After sonication, the homogenate was centrifuged at 13,000 rpm for 15 
min. The supernatant (200 μl, concentration of protein 25 mg/ml) was dissolved in a reaction 
volume of 600 μl of HO activity buffer containing 2 mg of liver cytosol (as a source of 
biliverdin reductase), 0.8mM nicotinamide dinucleotide phosphate, 20μM hemin, 2mM 
glucose-6-phosphate, and 0.016 U/μl glucose-6-phosphate dehydrogenase. The reaction was 
performed at 37°C for 1 h in the dark and stopped by addition of 600 μl of chloroform. After 
extraction of bilirubin, the chloroform layer was measured at 464 nm minus the background at 
530 nm. Based on the protein content in the reaction volume, the results are expressed as 
formation of bilirubin (pmol) per milligram of protein within 1 h. Spleen tissue of control rats 
served as a positive control. 
 
Statistical analysis 
Statistical analysis was performed using SPSS v. 11.0.1 (SPSS Inc. IL, USA). Data are 
expressed as means ± SD. Differences in measured variables between each group were 
assessed using a Mann-Whitney U test. Survival curves from the time of partial hepatectomy 
were calculated using the Kaplan-Meier method and analyzed by log-rank test. P < 0.05 was 
considered to indicate statistical significance. 
 
Results 




The time course of HO-1 protein expression in the liver after CoPP and OLP treatment 
was first determined in normal rats. As shown in Fig. 3A, hepatic HO-1 protein was barely 
detectable in the liver in untreated normal rats (control), but was detected 6 h after CoPP 
treatment and continued to increase until 24 h. A combination of single and continuous ip 
injection of OLP also led to an increase in hepatic HO-1 protein expression that reached 
approximately 2.5-fold higher than that in control animals at 6 h after the single ip injection of 
OLP, and was subsequently sustained at this level until 24 h (Fig. 3B). Although HO-1 
expression was decreased compared with those of previous time points at 48h after the single 
ip injection of OLP, it was significantly higher than that in control animals. In contrast, a 
single ip injection of OLP alone failed to increase HO-1 protein expression at any time points. 
Phosphorylated Akt protein was observed at 6 h after a single ip injection of OLP, and kept 
increased throughout a continuous injection of OLP (Fig. 3B). OLP treatment led to a strong 
increase of hepatic HO enzymatic activity that was approximately 3-fold higher than that in 
control animals at all time points, while ZnPP, a competitive inhibitor of heme oxygenase,
16
 
cancelled OLP-induced increase in HO activity in the liver (Fig. 3D) without affecting 
expression level of HO-1 protein (Fig. 3B, top vs. 3C, top). ZnPP also cancelled 
phosphorylation of Akt induced by OLP (Fig. 3B, 2nd panel vs. 3C, 2nd panel), suggesting 
that phosphorylation of Akt is dependent on HO enzymatic activity. Immunohistochemical 
analysis indicated that HO-1 was localized in non-parenchymal cells of liver obtained from 
control rats (Fig. 3E). In contrast, HO-1 was markedly increased in hepatocytes mainly 
located in the region around the central vein after CoPP or OLP treatment (Figs. 3F and G). 
 
Attenuation of SOS by cobalt protoporphyrin IX via induction of heme oxygenase-1 
In rats treated with MCT alone, macroscopic findings showed accumulation of bloody 
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ascites and the color of the liver surface had turned dark-red, indicating liver congestion, at 48 
h after MCT treatment. Histologically, sinusoidal hemorrhage and dilatation, endothelial 
damage of central veins, and coagulative necrosis of hepatocytes were observed 
predominantly in the mid- and centrilobular region (Fig. 4C). The mean score for HE staining 
indicated the presence of severe SOS, and excessive elevation of serum liver enzymes was 
observed (Table 1). RECA-1 protein expression in the liver was markedly reduced after MCT 
treatment compared with controls (Figs. 4B and D), which indicated that the sinusoidal lining 
had largely disappeared. In contrast, in animals treated with MCT+CoPP, bloody ascites had 
disappeared and the color of the liver surface was brown, similarly to controls. HE staining 
indicated little sinusoidal dilation and hemorrhage, endothelial damage of central veins, or 
coagulative necrosis of hepatocytes (Fig. 4E), and the mean score for HE staining was 
significantly lower than that after MCT treatment alone and indicated mild SOS. 
Immunohistochemical analysis showed that the level of RECA-1 protein expression in the 
liver of animals in the MCT+CoPP group was comparable to that in control rats (Fig. 4F), and 
pretreatment with CoPP led to a profound decrease in serum liver enzymes (AST and ALT) 
compared with MCT alone (P < 0.01). ZnPP abolished the protective effects of CoPP, as 
demonstrated by sinusoidal hemorrhage and dilation, endothelial damage of central veins, and 
coagulative necrosis of hepatocytes in the liver (Fig. 4G). The mean score for SOS was 
significantly higher in MCT+CoPP+ZnPP group than that in MCT+CoPP group (P < 0.01) 
and nearly as high as that in MCT group (Table 1). Immunohistochemical analysis indicated a 
marked decrease in RECA-1 expression in SECs (Fig. 4H), and serum biochemistry showed 
excessive elevation of liver enzymes (Table 1) in MCT+CoPP+ZnPP group. 
 
Olprinone inhibits MCT-induced SOS in an HO-1-dependent manner 
The effect of olprinone on SOS was examined using the protocol shown in Fig. 1. In the 
12 
 
MCT group, expression of HO-1 protein was low at 12 h after MCT treatment, whereas 
overexpression of HO-1 was observed in the MCT+OLP and MCT+OLP+ZnPP groups (Fig. 
5A). However, phosphorylation of Akt and upregulation of HO enzymatic activity compared 
with controls was observed only in the MCT+OLP group at 12 h after MCT treatment (Figs. 
5A and B). No evidence of SOS or elevation of liver enzymes was observed at 12 h in any 
group (data not shown). 
In the MCT group, macro- and microscopic findings at 48 h after MCT treatment 
indicated liver congestion and severe SOS (Figs 6A and B), which were quite similar with 
those of rats treated with MCT alone (Figs 4C and D). In contrast, pretreatment with OLP led 
to elimination of ascites formation and liver congestion, and HE staining indicated little 
sinusoidal alteration, endothelial damage of central veins, or coagulative necrosis of 
hepatocytes (Fig. 6C). The mean score for HE staining was significantly lower than that in the 
MCT group (P < 0.01) and indicated that SOS was absent. Immunohistochemistry indicated 
abundant expression of RECA-1 protein, suggesting that the sinusoidal lining was intact (Fig. 
6D). Elevation of liver enzymes was also blocked significantly by pretreatment with OLP 
(Table 2). These results were quite similar to those for MCT+CoPP treatment.  
In MCT+OLP+ZnPP group, macroscopically, bloody ascites and liver congestion were 
observed, and HE staining revealed sinusoidal hemorrhage and dilation, endothelial damage 
of central veins, and coagulative necrosis of hepatocytes in the liver (Fig. 6E). The mean score 
for HE staining indicated severe SOS, and was significantly higher than that for the 
MCT+OLP group (P < 0.01) and nearly as high as that for the MCT group (Table 2). 
Immunohistochemical analysis indicated a marked decrease in RECA-1 expression in SECs 
(Fig. 6F), and serum biochemistry showed excessive elevation of liver enzymes (Table 2). 




Preservation of remnant liver function by olprinone 
Kaplan-Meier curves for 10-day survival after partial hepatectomy are shown in Fig.7. 
The survival rate after hepatectomy in the MCT+OLP group was significantly higher than that 
in the MCT group (86.7% vs. 6.7%, P < 0.01). Blockage of HO activity by ZnPP resulted in a 
poor survival rate (13.3%) that did not differ significantly from the rate for the MCT group 
and was significantly lower than the rate for the MCT+OLP group (P < 0.01), indicating that 
ZnPP completely eliminated the preservation of remnant liver function by OLP. 
 
Discussion 
Since the first report of SOS in Jamaican patients who had ingested pyrrolizidine 
alkaloids, it has emerged that various pharmacological agents, including oxaliplatin, cause 
SOS. In the current study, we used a rat model of monocrotaline (MCT)-induced SOS to 
search for a therapeutic strategy for prevention of SOS. Monocrotaline is a pyrrolizidine 
alkaloid found in Crotalari, and the MCT-induced SOS rat model has the same histological 
characteristics as the human disease, including sinusoidal dilation and hemorrhage, 
endothelial damage of central veins, and necrotic hepatocytes in the liver, as well as similar 
“clinical features” of hyperbilirubinemia, hepatomegaly, and ascites formation.21  
The mechanism of MCT-induced SOS has been examined in vitro and in vivo, as 
described by Deleve et al.
8
 The first step of SOS is SEC-specific injury induced by the 
reactive metabolite of MCT. Subsequently, morphological alteration of SECs and degradation 
of the sinusoidal lining due to matrix metalloproteinases (MMPs) released from SECs occur 
12 h after MCT treatment and result in disturbance of the hepatic microcirculation.
8
 
Prospective studies for prevention of SOS have been conducted from the perspective of 
improvement of hepatic microcirculation using prostaglandin E1 or heparin, but these drugs 
do not reduce the incidence of fatal SOS.
22
 Hence, treatment of dysfunction of the hepatic 
14 
 
microcirculation due to SEC damage is insufficient to overcome SOS.  
In contrast, pretreatment with MMP inhibitors started 24 h before MCT treatment led to 
amelioration of MCT-induced rat SOS.
23
 Furthermore, in a recent retrospective study, Ribero 
et al. demonstrated that addition of bevacizumab, a recombinant human monoclonal antibody 
to vascular endothelial growth factor (VEGF)-A, in 5FU-plus-oxaliplatin chemotherapy led to 
reduction of the incidence and severity of oxaliplatin-induced SOS.
24
 The mechanism of a 
bevacizumab-mediated hepatoprotection was suggested to be due to VEGF blockage, which 
may attenuate damage to SECs by downregulating MMP production. Therefore, protection 
against SEC damage may offer a preventive strategy for SOS. In this study, however, CoPP or 
OLP do not attenuate SOS with simultaneous administration with MCT (data not shown). In 
contrast, prophylactic upregulation of HO-1 by pretreatment with CoPP or OLP was effective 
for blockage of SOS, and collectively the current and previous data indicate that prophylactic 
protection of SECs has therapeutic potential for prevention of SOS. 
HO-1 is the rate-limiting enzyme of heme catabolism, catalyzing the breakdown of heme 
into biliverdin, iron, and carbon monoxide.
25
 Recent studies have demonstrated that HO-1 
expression and associated metabolites have cytoprotective properties including anti-apoptotic 
effects through activation of the Akt signaling pathway, 
26
 anti-inflammatory effects due to 
inhibition of production of inflammatory cytokines, 
27
 and anti-oxidant effects via an increase 
in expression and catalytic activity of superoxide dismutase in vascular endothelial cells. 
28
 In 
the current study, prophylactic upregulation of HO-1 by CoPP maintained the integrity of 
SECs in MCT-treated rats, as indicated by sustained RECA-1 protein expression, and this 
resulted in inhibition of the occurrence of SOS. These results suggest that HO-1 may have 
therapeutic potential for various diseases, but to date no clinical trials associated with HO-1 
have been reported. Most in vivo studies have shown beneficial effects of CoPP-induced 
HO-1 expression,
29,28
 but side effects observed in animal studies have made it difficult to use 
15 
 
CoPP in a clinical setting.
30
 Therefore, we examined induction of HO-1 expression using 
olprinone (OLP), a drug that has been proven to be safe for clinical applications. 
OLP is a new selective PDE III inhibitor with combined positive inotropic and 
vasodilating properties mediated through elevation of intracellular cyclic adenosine 
monophosphate (cAMP) levels in vascular smooth muscle cells and cardiomyocytes by 
preventing degradation of cAMP.
31
 Abundant PDE III is present in the liver,
32
 and in vivo 
studies using PDE III inhibitors have shown beneficial effects on hepatic ischemia-reperfusion 
injury.
14,33
 However, the precise mechanism by which PDE III inhibitors protect the liver 
remains unclear. In the current study, we showed a correlation of cytoprotective properties of 
a PDE III inhibitor and HO-1, since treatment with OLP (similarly to CoPP) led to 
overexpression of HO-1 protein and upregulation of HO enzymatic activity in the liver in the 
presence or absence of MCT. Furthermore, we found that OLP activated (phosphorylated) Akt, 
which is known as a major regulator of cell survival and reported to protect mitochondrial 
membrane potential from reactive oxygen species and inactivates proapoptotic protein.
34
 
ZnPP abolished the activation of Akt, indicating that OLP-induced activation of Akt was 
mediated by HO. Pretreatment with OLP protects SECs from MCT toxicity, as shown by 
maintenance of RECA-1 protein expression, and inhibits the occurrence of SOS, as indicated 
by the absence of histopathological features of SOS and the lack of elevation of plasma liver 
enzymes. Furthermore, blockage of HO activity by administration of ZnPP abolished 
OLP-mediated phosphorylation of Akt and canceled hepatoprotection in OLP-pretreated rats. 
These results suggest that OLP-induced HO-1 exerts its cytoprotective property through 
activation of survival signaling pathway, Akt, and the hepatoprotective effect of OLP is 
approximately equal to that of CoPP, despite reduced upregulation of expression of HO-1 by 
OLP compared to CoPP. 
Vauthey et al reported that oxaliplatin was associated with an increase in sinusoidal injury 
16 
 
but no increase in perioperative morbidity or mortality,
7
 whereas Nakano et al reported 
sinusoidal injury induced by oxaliplatin-contained chemotherapy resulted in a poor liver 
functional reserve as shown by a high value of preoperative ICG-R15 and was associated with 
higher morbidity and longer hospital stay in patients presenting with sinusoidal injury.
10
 
Therefore, strategy for preserving liver functional reserve should be required to perform safe 
liver resection in patients received oxaliplatin-contained chemotherapy. In the present study, 
we showed that pretreatment with OLP gave a significant improvement in survival rate after 
hepatic resection in MCT-treated rats. This result suggests that OLP treatment not only blocks 
SOS histopathologically, but also preserves remnant liver function after major hepatectomy. 
OLP has been widely used in various clinical situations and may be promising for inhibition 
of SOS induced by chemotherapy. However, a recent study indicated that HO-1 has a potential 
progressive role in cancer cells,
35
 and the effect of PDE III inhibitors on cancer cells remains 
unknown. Therefore, further investigation will be necessary before clinical application of OLP 
in patients with HCRM. 
In summary, the current results show that prophylactic upregulation of HO-1 by CoPP or 
olprinone is effective for maintenance of the sinusoidal lining in SECs and blockage of 
MCT-induced SOS. Pretreatment with OLP also led to a significant improvement in survival 
rate after hepatectomy in MCT-treated rats. These results suggest that OLP may offer a 
therapeutic strategy for preventing SOS by protection of SECs from drug-induced injury 
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Figure 1: Liver sections of human SOS (left column, A and C) and sections taken from rats 
after treatment with 90 mg/kg MCT (right column, B and D). HE staining (A and B, 400×) 
revealed sinusoidal congestion and dilatation. The arrowheads indicate the area of coagulative 
necrosis of hepatocytes. Masson-Trichrome staining (C and D, 400×) showed peri-central 
fibrosis. 
Figure 2: Experimental protocol. In all animals, an osmotic pump was inserted into the 
peritoneal cavity under anesthesia with sevoflurane to permit continuous ip injection of OLP 
or distilled water. At 12 h after insertion of the osmotic pump, MCT (90 mg/kg) was 
administered by gavage and a single ip injection of distilled water, OLP, or OLP and ZnPP 
was given. Blood and liver samples were collected at 12 and 48 hours after MCT treatment. 
MCT: monocrotaline, ip: intraperitoneal, OLP: olprinone, ZnPP: zinc protoporphyrin IX. 
Figure 3: Western blotting analysis of hepatic HO-1 and α-tubulin, and HO-1, phosphorylated 
Akt, Akt, and α-tubulin in representative livers treated with (A) cobalt protoporphyrin IX 
(CoPP) and (B) olprinone (OLP), respectively. Relative HO-1 protein levels were quantified 
by densitometry. Data are expressed as means ± SD (n = 4, * P < 0.01 vs. control; ** P < 0.05 
vs. control). Control indicates an untreated normal rat. (C) Western blotting analysis of 
hepatic HO-1 and α-tubulin, and HO-1, phosphorylated Akt, Akt, and α-tubulin in 
representative livers treated with OLP+ZnPP. (D) HO enzymatic activity in rat livers from 
OLP-treated rats and OLP+ZnPP-treated rats. Data are expressed as means ± SD (n = 4, † P < 
0.01 vs. control; †† P < 0.05 vs. control; ‡ P < 0.05 vs. OLP treatment at each time). Liver 
sections from control (E), OLP-treated (F), and CoPP-treated (G) rats were subjected to 
immunohistochemical analysis to determine expression patterns of HO-1 protein. HO-1: heme 
oxygenase-1, OLP: olprinone, CoPP: cobalt protoporphyrin IX. 
Figure 4: Representative photomicrographs of rat livers. The left column (A, C, E, and G) 
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shows HE staining (x 400) and the right column (B, D, F, and H) shows 
immunohistochemistry of RECA-1 (x 400). (A) In the control group there was no evidence of 
sinusoidal alteration, endothelial damage of central veins, or coagulative necrosis of 
hepatocytes. (B) Immunohistochemical analysis in the control group indicated RECA-1 
protein expression in the sinusoidal lining. (C) Treatment with MCT alone resulted in severe 
sinusoidal hemorrhage, endothelial damage of central veins, and coagulative necrosis of 
hepatocytes. (D) With MCT alone, RECA-1 protein expression was significantly reduced 
compared with that in the control group. (E) Induction of HO-1 by pretreatment with CoPP 
led to amelioration of pathohistological changes in the liver induced by MCT treatment. (F) 
Induction of HO-1 also restored RECA-1 protein expression to the level in the control group. 
(G and H) However, inhibition of HO activity by ZnPP canceled CoPP-provided 
hepatoprotective effect. MCT: monocrotaline, CoPP: cobalt protoporphyrin IX, RECA-1: rat 
endothelial cell antigen-1. 
Figure 5: (A) Western blotting analysis of hepatic HO-1, phosphorylated Akt, and Akt protein 
in representative livers obtained from control (untreated) and treated groups at 12 h after 
treatment. Relative HO-1 protein levels were quantified by densitometry. Data are expressed 
as means ± SD (n = 3, * P < 0.01 vs. control). (B) HO enzymatic activity in rat livers from 
each group at 12 h after treatment. Data are expressed as means ± SD (n = 3, † P < 0.01 vs. 
MCT+OLP+ZnPP). 
Figure 6: Representative photomicrographs of rat livers. The left column (A, C and E) shows 
HE staining (x 400) and the right column (B, D and F) shows immunohistochemistry of 
RECA-1 (x 400). (A and B) In MCT group, severe sinusoidal hemorrhage, endothelial 
damage of central veins, and coagulative necrosis of hepatocytes were observed, together with 
significant reduction of RECA-1 protein expression. (C and D) Pretreatment with OLP led to 
blockage of sinusoidal changes induced by MCT treatment and increased RECA-1 protein 
23 
 
expression compared with MCT group. (E and F) ZnPP treatment completely inhibited the 
protective effects of pretreatment with OLP. 
Figure 7: Kaplan-Meier curves for 10-day survival after partial hepatectomy. Full line (    ), 
broken line (    ), and dotted line (    ), indicate survival curves of MCT, MCT+OLP and 
MCT+OLP+ZnPP, respectively (10-day survival rates: MCT, 6.7%; MCT+OLP, 86.7%; 
MCT+OLP+ZnPP, 13.3%). The survival rate in MCT+OLP was significantly higher than in 
MCT and MCT+OLP+ZnPP (P < 0.01). RECA-1: rat endothelial cell antigen-1, HO: heme 
oxygenase. 
1Table 1. SOS score for HE staining and serum biochemistry after CoPP administration
Item Control MCT alone MCT+CoPP MCT+CoPP+ZnPP
SOS score 0 7.5 ± 1.4 2.8 ± 0.5 * 8.3 ± 1.2 †
AST (IU/l) 87.4 ± 33.2 3300.0 ± 991.0 196.6 ± 83.2 * 3498.8 ± 644.2 †
ALT (IU/l) 48.4 ± 10.2 2072.0 ± 882.5 163.4 ± 73.1 * 1846.8 ± 245.4 †
Data are shown as means ± SD. * P < 0.01 compared with MCT alone. † P < 0.01 compared 
with MCT+CoPP. Control indicates rats treated with PBS instead of MCT.
MCT, monocrotaline; CoPP, cobalt protoporphyrin IX; SOS, sinusoidal obstruction syndrome; 
AST, aspartate aminotransferase; ALT, alanine aminotransferase
Table
2Table 2. SOS score for HE staining and serum biochemistry after OLP administration
Item MCT MCT+OLP MCT+OLP+ZnPP
SOS score 7.7 ± 1.5 1.8 ± 1.0 * 7.8 ± 1.9 †
AST (IU/l) 3752.5 ± 1172.8 269.7 ± 162.0 * 5658.3 ± 3762.6 †
ALT (IU/l) 2466.3 ± 933.1 146.8 ± 69.8 * 2778.3 ± 1636.2 †
Data are shown as means ± SD. * P < 0.01 compared with MCT, † P < 0.01 compared with 
MCT+OLP.  MCT, monocrotaline; OLP, olprinone; ZnPP, zinc protoporphyrin IX; SOS, 
sinusoidal obstruction syndrome; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase









0 24 h 48 h
-12h




Samples (n = 6)
12 h
Samples (n = 3)
OLP 0.6μg/kg/h continuous ip
OLP; 2.0mg/kg ip
MCT; 90mg/kg orally





0 24 h 48 h
12 h
Samples (n = 3)
-12h





0 24 h 48 h12 h
Samples (n = 3)























































































































































































































































Sinusoidal obstruction syndrome (SOS) induced by chemotherapy is of concern in 
hepatectomy for patients with hepatic colorectal metastases. We succeeded in inhibiting the 
occurrence of SOS in a rat model through induction of heme oxygenase-1 by pretreatment 
with olprinone, a phosphodiesterase III inhibitor.
* MiniAbstract
1Structured Abstract
Objective: The aim of study was to investigate pharmacological treatment for sinusoidal 
obstruction syndrome (SOS).
Background: SOS is associated with oxaliplatin-based chemotherapy in patients with hepatic 
colorectal metastases. Patients with SOS have increased postoperative morbidity after major 
hepatectomy, but a method for effective prevention of SOS has not been established.
Methods: Male Sprague-Dawley rats were treated with cobalt protoporphyrin IX (CoPP) or
olprinone (OLP), a phosphodiesterase III inhibitor, and hepatic HO-1 expression and HO 
enzymatic activity were determined. Monocrotaline (MCT) was given to rats to induce SOS,
and blockage of SOS by CoPP or OLP-induced hepatic HO-1 was examined in these rats. 
Zinc protoporphyrin IX (ZnPP), a competitive HO inhibitor, was given to MCT-treated rats 
together with OLP to clarify the mechanism of protection against SOS. We also examined if
OLP preserved remnant liver function after 70% hepatectomy in MCT-treated rats.
Results: OLP upregulated hepatic HO-1 protein expression and HO enzymatic activity, and 
activated Akt protein. Administration of ZnPP to OLP-treated rats resulted in inhibition of HO 
activity and inactivation of Akt. Induction of HO-1 by pretreatment with CoPP led to 
amelioration of SOS in histological findings and blockage of elevation of serum liver 
enzymes. Pretreatment with OLP gave a similar result and preserved remnant liver function, 
as indicated by improved survival after hepatectomy. ZnPP completely abolished the
protective effects of OLP.
Conclusions: Protection of the liver from drug-induced injury by prior upregulation of HO-1 
using OLP may have potential as a therapeutic strategy for prevention of SOS.
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